Physicians from Texas Colon & Rectal Specialists, a colorectal practice in North Texas, a part of Texas Oncology, have joined The US Oncology Network.
The American Society of Clinical Oncology is launching an internship program for medical students from populations underrepresented in medicine.
City of Hope has signed an education agreement with Hospital Israelita Albert Einstein, a cancer center in Brazil.
The Pascale Foundation (Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”) has joined the Caris Precision Oncology Alliance.
The FY21 Defense Appropriations Act provides funding to the Department of Defense Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.
The FY21 Defense Appropriations Act provides funding to the Department of Defense Breast Cancer Research Program to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for service members, veterans, and the general public.
Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai.
Tumors consume glucose at high rates, but a team of researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.
Sacituzumab govitecan was granted regular FDA approval for patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.
FDA has approved a new dosage regimen of 500 mg/m2 as a 120-minute intravenous infusion every two weeks for cetuximab for patients with K-Ras wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck.
